中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2013年
8期
5-7
,共3页
于成勇%林荣海%李振光%张道强
于成勇%林榮海%李振光%張道彊
우성용%림영해%리진광%장도강
心房颤动%脂蛋白相关性磷脂酶A2%缺血性卒中%阿托伐他汀
心房顫動%脂蛋白相關性燐脂酶A2%缺血性卒中%阿託伐他汀
심방전동%지단백상관성린지매A2%결혈성졸중%아탁벌타정
Atrial fibrillation%Lipoprotein-associated phospholipase A2%Ischemic stroke%Atorvastatin
目的 观察非瓣膜性心房颤动(NVAF)患者血浆脂蛋白相关性磷脂酶A2 (LP-PLA2)含量变化的特点及他汀类药物的影响.方法 测定169例NVAF患者和124例正常对照者血浆LP-PLA2含量,并进行比较.将169例NVAF患者随机分为NVAF对照组(n=52)、阿司匹林组(n=61)和阿司匹林加阿托伐他汀组(n=56),NVAF对照组不予任何处理,阿司匹林组予阿司匹林(100 mg/d),阿司匹林加阿托伐他汀组予阿司匹林(100 mg/d)和阿托伐他汀(10 mg/d).检测三组患者治疗前和治疗后3个月、1年时的血浆LP-PLA2含量.结果 NVAF患者血浆LP-PLA2为(187±14) ng/ml,显著高于正常对照者的(147±14) ng/ml (P＜0.01).治疗前及治疗后3个月、1年时,NVAF对照组血浆LP-PLA2含量分别为(187±14)、(190±16)和(196±16) ng/ml,差异无统计学意义；阿司匹林组LP-PLA2分别为(191±15)、(179±12)和(165±15) ng/ml,治疗后LP-PLA2较治疗前显著下降(P＜0.01)；阿司匹林加阿托伐他汀组LP-PLA2分别为(193±16)、(152±14)和(141±12) ng/nl,治疗后LP-PLA2较治疗前显著下降(P＜0.01),且较阿司匹林组下降更明显(P＜0.01).结论 NVAF患者血浆LP-PLA2含量显著升高.阿司匹林与阿托伐他汀联合应用可更显著降低血浆LP-PLA2含量.NVAF患者在实施抗栓治疗时可考虑加用他汀类药物.
目的 觀察非瓣膜性心房顫動(NVAF)患者血漿脂蛋白相關性燐脂酶A2 (LP-PLA2)含量變化的特點及他汀類藥物的影響.方法 測定169例NVAF患者和124例正常對照者血漿LP-PLA2含量,併進行比較.將169例NVAF患者隨機分為NVAF對照組(n=52)、阿司匹林組(n=61)和阿司匹林加阿託伐他汀組(n=56),NVAF對照組不予任何處理,阿司匹林組予阿司匹林(100 mg/d),阿司匹林加阿託伐他汀組予阿司匹林(100 mg/d)和阿託伐他汀(10 mg/d).檢測三組患者治療前和治療後3箇月、1年時的血漿LP-PLA2含量.結果 NVAF患者血漿LP-PLA2為(187±14) ng/ml,顯著高于正常對照者的(147±14) ng/ml (P＜0.01).治療前及治療後3箇月、1年時,NVAF對照組血漿LP-PLA2含量分彆為(187±14)、(190±16)和(196±16) ng/ml,差異無統計學意義；阿司匹林組LP-PLA2分彆為(191±15)、(179±12)和(165±15) ng/ml,治療後LP-PLA2較治療前顯著下降(P＜0.01)；阿司匹林加阿託伐他汀組LP-PLA2分彆為(193±16)、(152±14)和(141±12) ng/nl,治療後LP-PLA2較治療前顯著下降(P＜0.01),且較阿司匹林組下降更明顯(P＜0.01).結論 NVAF患者血漿LP-PLA2含量顯著升高.阿司匹林與阿託伐他汀聯閤應用可更顯著降低血漿LP-PLA2含量.NVAF患者在實施抗栓治療時可攷慮加用他汀類藥物.
목적 관찰비판막성심방전동(NVAF)환자혈장지단백상관성린지매A2 (LP-PLA2)함량변화적특점급타정류약물적영향.방법 측정169례NVAF환자화124례정상대조자혈장LP-PLA2함량,병진행비교.장169례NVAF환자수궤분위NVAF대조조(n=52)、아사필림조(n=61)화아사필림가아탁벌타정조(n=56),NVAF대조조불여임하처리,아사필림조여아사필림(100 mg/d),아사필림가아탁벌타정조여아사필림(100 mg/d)화아탁벌타정(10 mg/d).검측삼조환자치료전화치료후3개월、1년시적혈장LP-PLA2함량.결과 NVAF환자혈장LP-PLA2위(187±14) ng/ml,현저고우정상대조자적(147±14) ng/ml (P＜0.01).치료전급치료후3개월、1년시,NVAF대조조혈장LP-PLA2함량분별위(187±14)、(190±16)화(196±16) ng/ml,차이무통계학의의；아사필림조LP-PLA2분별위(191±15)、(179±12)화(165±15) ng/ml,치료후LP-PLA2교치료전현저하강(P＜0.01)；아사필림가아탁벌타정조LP-PLA2분별위(193±16)、(152±14)화(141±12) ng/nl,치료후LP-PLA2교치료전현저하강(P＜0.01),차교아사필림조하강경명현(P＜0.01).결론 NVAF환자혈장LP-PLA2함량현저승고.아사필림여아탁벌타정연합응용가경현저강저혈장LP-PLA2함량.NVAF환자재실시항전치료시가고필가용타정류약물.
Objective To investigate the changes of plasma lipoprotein-associated phospholipase A2 (LP-PLA2) levels in patients with nonvalvular atrial fibrillation (NVAF) and the effects of statins.Methods The changes of plasma LP-PLA2 levels were determined in 169 cases of NVAF who didn' t recieve any antithrombotic therapy and 124 cases controls,and the difference between them was compared.One hundred and sixty-nine NVAF patients were randomly divided into three groups:52 cases in NVAF control group,61 cases in aspirin group and 56 cases in aspirin combined with atorvastatin group.Patients in NVAF control group didn't recieve any treatment,the aspirin group was given aspirin 100 mg/d,and the aspirin combined with atorvastatin group was given aspirin 100 mg/d + atorvastatin 10 mg/d.The content of plasma LP-PLA2 levels were determined by ELISA among the three groups before treatment and 3 months,1 year after treatment.Results LP-PLA2 levels were significantly increased in NVAF group [(187 ± 14) ng/L],compared with controls [(147 ± 14) ng/L] (P ＜ 0.01).Before treatnent,3 months and 1 year after treatment,the content of plasma LP-PLA2 levels were (187 ±14),(190 ± 16),(196 ± 16) ng/L in NVAF group respectively,the difference had no statistical significance(P ＞0.05).The content of plasma LP-PLA2 levels were (191 ± 15),(179 ± 12),(165 ±15)ng/L in aspirin group respectively,and the LP-PLA2 levels were significant decreased after treatment,compared with brfore treatment(P ＜0.01) ; The content of plasma LP-PLA2 levels were (193 ±16),(152 ± 14),(141 ± 12) ng/L in aspirin combined with atorvastatin group respectively,the LP-PLA2 levels were significant decreased after treatment,compared with before treatment(P ＜ 0.01),and it was significantly decreased than that in aspirin group(P ＜ 0.01).Conclusions The plasma LP-PLA2 levels were significantly elevated in NVAF.The content of plasma LP-PLA2 levels were significant decreased by aspirin combined with atorvastatin,statins had neuroprotective effects and may be as a new anti-inflammation agent used in antithrombotic therapy of NVAF patients.
